Clinical Trials
91 trialsTrial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Canadian Cancer Trials Group
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Eastern Cooperative Oncology Group
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Eastern Cooperative Oncology Group
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Eastern Cooperative Oncology Group
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Memorial Sloan Kettering Cancer Center
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
AntiCD-66
University of Southampton
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
DMV
University of California, San Francisco
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
M.D. Anderson Cancer Center
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
M.D. Anderson Cancer Center
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Mayo Clinic
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Alliance for Clinical Trials in Oncology
Lenalidomide and High-Dose Melphalan
M.D. Anderson Cancer Center
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
M.D. Anderson Cancer Center
MPTD
University of Turin, Italy
CARMYSAP
Nantes University Hospital
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
University of Arizona